Improving immune response in pancreatic cancer using dendritic cells
Re-wiring PDAC Tumor Immunity Through Dendritic Cells
This study is looking at ways to boost the immune system in people with pancreatic cancer by fixing certain immune cells that aren't working properly, hoping to make current treatments like radiation more effective and improve patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10912661 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune response in patients with pancreatic ductal adenocarcinoma (PDAC) by targeting specific immune cells known as conventional dendritic cells (cDCs). The study investigates how these cells are dysfunctional in PDAC patients and explores methods to restore their function through a combination of treatments. By using agents like FMS-like tyrosine kinase 3 ligand (FLT3L) and CD40 agonists, the research aims to improve the effectiveness of existing therapies, such as radiation, in generating a robust immune response against tumors. Patients may benefit from a more effective treatment strategy that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immune responses and better treatment outcomes for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promise in enhancing immune responses in cancer treatment using similar approaches, indicating potential for success in this area.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.